Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study.
Suresh R RamalingamSilvia NovelloSalih Zeki GucluDmitry BentsionZanete ZvirbuleMaria SzilasiReyes BernabeKonstantinos SyrigosLauren Averett ByersPhilip ClinganJair BarEverett E VokesRamaswamy GovindanMartin DunbarPeter AnsellLei HeXin HuangVasudha SehgalJaimee GlasgowBruce A BachJulien MazieresPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
In current smokers with advanced sqNSCLC, there was no therapeutic benefit of adding veliparib to first-line chemotherapy. The LP52 signature may identify a subgroup of patients likely to derive benefit from veliparib with chemotherapy.